The Galway medtech startup led by Brian Shields has closed an oversubscribed Series C financing round for its Neuromark medical device that treats chronic rhinitis.
MVM Partners led the funding round, with “significant” participation from Sofinnova Partners, while further funding came from existing investors EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland. Kyle Dempsey, partner at MVM Partners, and Cedric Moreau, partner at Sofinnova Partners will also join as board directors.
The company’s innovative Neuromark medical device employs its proprietary Impedance Controlled Radiofrequency technology to target the overactive posterior nasal nerves (PNN) that drive the symptoms of chronic rhinitis, which affects millions worldwide.
“I am delighted to welcome MVM Partners and Sofinnova Partners to the Neurent Medical team, two global leaders in medtech investing,” said co-founder and CEO of Neurent Medical, Brian Shields. “This Series C financing will support our commercial expansion and help bring Neuromark to the patients and physicians who need it most.”
“Millions of patients suffer from chronic rhinitis, and posterior nasal nerve ablation represents a powerful tool to provide proven relief,” said MVM’s Dempsey. “In this rapidly emerging category, Neurent has set a new standard with a best-in-class solution, powered by a proprietary impedance control system that delivers real-time feedback, giving clinicians greater treatment confidence, control, and predictability during every procedure.”
“Neurent Medical has developed a truly differentiated approach supported by a growing body of clinical evidence demonstrating meaningful and durable patient benefit,” added Cedric Moreau. “We also see significant potential to expand this platform into additional indications, and we are confident in our partnership with Neurent Medical at this pivotal stage of commercial growth.”
Shields says that the new investment will allow it to expand patient access, enable further evidence generation across broader populations and support the continued development of its pipeline offerings.
Shields was a speaker at our Founders Exchange event back in 2025 where he offered fellow start-ups his learnings and advice on fundraising, as well as emphasising the importance of building a superb team, something he said was vital when Neurent was setting up its own manufacturing facility in Oranmore. At the time of the launch Neurent said it would create 125 highly skilled jobs by the end of 2028, with roles in engineering, quality control, operations, supply chain, sales and marketing.
Don’t miss out on the knowledge you need to succeed. Sign up for the Daily Brief, Silicon Republic’s digest of need-to-know sci-tech news.